Enliven Therapeutics (NASDAQ:ELVN) Given New $56.00 Price Target at HC Wainwright

Enliven Therapeutics (NASDAQ:ELVN) had its price target lifted by research analysts at HC Wainwright from $48.00 to $56.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s target price points to a potential upside of 57.61% from the company’s current price.

Other analysts have also issued research reports about the company. Mizuho increased their price objective on Enliven Therapeutics from $41.00 to $45.00 and gave the company an “outperform” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Wednesday, January 21st. Finally, Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.40.

Enliven Therapeutics Stock Performance

Shares of Enliven Therapeutics stock opened at $35.53 on Thursday. The stock has a market capitalization of $2.12 billion, a price-to-earnings ratio of -19.10 and a beta of 0.33. The company has a fifty day moving average of $28.04 and a 200-day moving average of $22.72. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $36.72.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.06). On average, equities research analysts forecast that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, insider Joseph P. Lyssikatos sold 5,000 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $29.04, for a total transaction of $145,200.00. Following the transaction, the insider directly owned 740,188 shares of the company’s stock, valued at approximately $21,495,059.52. The trade was a 0.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Benjamin Hohl sold 10,000 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $29.58, for a total transaction of $295,800.00. Following the completion of the sale, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $1,508,580. This represents a 16.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 232,180 shares of company stock worth $6,217,033. 25.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Enliven Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets grew its stake in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP raised its holdings in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after purchasing an additional 1,434 shares in the last quarter. AlphaQuest LLC purchased a new position in Enliven Therapeutics during the third quarter valued at $96,000. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock valued at $106,000 after buying an additional 3,490 shares in the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.